Bristol Myers Squibb plans to invest approximately $2.3 billion in a new manufacturing campus at Generation Park in Houston, Texas, expanding its U.S. production capabilities for next-generation medicines.
The project is part of BMS’ previously announced $40 billion commitment to invest in U.S. research and development, technology and domestic manufacturing over five years. The Houston campus is expected to create nearly 500 skilled jobs and is being designed to expand in scale and capability over time.
The approximately 600,000-square-foot facility will use a modular, multi-modal design that allows BMS to add or reconfigure manufacturing capacity as its pipeline and commercial requirements evolve.
The campus is expected to manufacture several types of medicines, including small molecules, biologics and antibody-drug conjugates. It will support drug product and finished goods manufacturing from late-stage development through product launch.
BMS said the site’s architecture is also being designed to accommodate future advances in digital integration and automation, allowing manufacturing capabilities to be brought online as pipeline needs change.
The company selected Houston following a competitive evaluation of markets across the Central and Eastern U.S. Factors included the region’s emerging life sciences workforce, incentives, access to utilities and transportation infrastructure and its broader business environment.
Generation Park spans approximately 4,300 acres and is focused on industries including life sciences and advanced manufacturing. BMS expects the new campus to initially employ nearly 500 people across operations, production, maintenance, engineering, quality and site administration.
The company also expects the project to generate approximately 2,000 construction and other indirect jobs between 2027 and 2030 as the facility is built and brought online.
BMS already has a presence in Texas through a contract manufacturer supporting commercial and clinical trial manufacturing. The company also operated 250 clinical trial sites across the state in 2025.
The Houston project is intended to strengthen BMS’ domestic pharmaceutical supply chain while providing additional manufacturing flexibility across multiple therapeutic modalities.
BMS invested approximately $10 billion in research and development in 2025 as part of its broader effort to develop new medicines.
KEY QUOTES:
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation. As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb
“Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation.”
Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb
